FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?
forum
JUBILANT Share Price Discussion
Jubilant Life Sciences Ltd.
NSE: JUBILANT | BSE: 530019 | ISIN: INE700A01033 | Sector: Pharmaceuticals and health care
N
Reputation: 4,625 • Jun 15 1:51 AM
Buy Jubilant Life Sciences, target price Rs 867: Anand Rathi
The brokerage continues to remain positive on the company on a medium to longer term perspective and maintains a buy rating on the stock.
The brokerage continues to remain positive on the company on a medium to longer term perspective and maintains a buy rating on the stock.
The Economic Times
Like
Reply
NSE:JUBILANT price when posted: 592.6
Recent posts in JUBILANT
N
Reputation: 4,625 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 29 3:08 AM
Dr Reddy's expects to launch Remdesivir in August
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
Moneycontrol
Like
Reply